About BPC-157

BPC-157 — Body Protection Compound-157 — is a synthetic peptide consisting of 15 amino acids, derived from a protective protein found naturally in the human stomach. Its primary purpose is to accelerate the repair of damaged tissues, particularly those with poor natural blood supply.

BPC-157 is designed to "bridge the gap" between the body's natural inflammatory response and the successful remodeling of functional tissue — meaning it doesn't mask symptoms, it restarts the repair process at the biological level.

• BPC-157 is a compounded peptide prescribed by a licensed provider for tissue repair, injury recovery, and gastrointestinal health
• It has been studied in preclinical models for its role in musculoskeletal healing, gut mucosal integrity, and anti-inflammatory activity
• It is administered as a subcutaneous injection and prescribed as a personalized, physician-supervised protocol

How It Works

BPC-157 facilitates four core biological processes that lead to faster, more integrated healing:

Vascularization (Angiogenesis) BPC-157 signals the body to build new micro-vessels into damaged areas — a process called angiogenesis. This is critical for tendons and ligaments, which are notoriously slow to heal because they naturally lack a robust blood supply. Without adequate blood flow, the cellular machinery needed for repair can't reach the injury site. BPC-157 effectively re-vascularizes areas of chronic or acute damage.

Tissue Synthesis BPC-157 stimulates fibroblasts — the cells that build connective tissue — and osteoblasts (bone-building cells) to migrate to the site of an injury and begin structural repairs.

Mucosal Protection In the digestive tract, BPC-157 facilitates the repair of the "tight junctions" in the gut lining. This prevents systemic inflammation caused by intestinal permeability (leaky gut) and is the basis for BPC-157's well-documented effects on gastrointestinal health.

Nitric Oxide Balancing BPC-157 helps regulate blood flow and reduces oxidative stress, which protects organs and nervous system tissue from toxic or physical trauma.

Two Distinct Indications

BPC-157 is clinically relevant for two patient profiles, and the indication shapes how the protocol is designed:

Musculoskeletal patients

• Acute injuries: ACL/MCL tears, rotator cuff strains, Achilles tendinosis
• Chronic wear-and-tear: tendinitis, bursitis, arthritis that hasn't responded to NSAIDs or physical therapy
• Post-surgical tissue repair and recovery
• Chronic overuse injuries where structural healing has plateaued

Gastrointestinal patients

• IBD-type inflammation, gastric ulcers, intestinal permeability (leaky gut)
• Post-antibiotic gut disruption
• GI side effects from GLP-1 medications or chronic NSAID use
• Systemic symptoms driven by gut integrity issues (fatigue, brain fog, immune dysregulation)

BPC-157 is one of very few peptides with direct, well-documented evidence of action on gut mucosa — making it uniquely positioned for patients whose primary concern is gastrointestinal rather than musculoskeletal.

What to Expect: Your First 90 Days

Days 1–30: Foundation You've settled into the weekday cadence — 20 units each morning, Monday through Friday. Most patients report less baseline soreness after training, easier sleep, and the first hints that a nagging spot is starting to quiet down. Gut-focused patients often notice calmer digestion in this window.

Days 30–60: Building The repair signal is fully online. Stubborn tendon, ligament, or joint spots typically feel more durable, day-after stiffness eases, and range of motion improves. Many people start pushing activity intensity back up without paying for it the next day.

Days 60–90: Peak Response Return-to-performance territory. Flare-ups are less frequent, gut comfort holds, and you and your physician decide together whether to wrap the block or run a little longer — up to 12 weeks on protocol.

Note: Results vary by individual and indication. Angiogenic repair mechanisms require two to six weeks for structural signals to become noticeable. Your care team will set realistic expectations at intake.

Safety Considerations

BPC-157 is generally well tolerated in the clinical context in which it is prescribed.

Who should not use BPC-157

• Patients with active cancer or a history of cancer: BPC-157's angiogenic activity creates new blood vessels — there is a theoretical connection that this could inadvertently support tumor growth or metastasis if cancer cells are present. It is strictly avoided in these patients.
• Pregnant or breastfeeding patients: BPC-157 is strictly contraindicated due to a complete lack of clinical safety data regarding fetal development and maternal hormone stability. This includes patients planning to become pregnant in the near future.
• Children and adolescents: Not recommended for pediatric use.

Common side effects The most common reported effects are mild, transient injection site reactions:

• Redness or itching — a minor inflammatory response at the site of the injection
• Bruising — common if a small blood vessel is nicked during subcutaneous administration
• Localized soreness — a "dull ache" at the injection site that usually dissipates within an hour

Drug interactions BPC-157 is generally well-tolerated due to its biological similarity to compounds found in human gastric juice. Your prescribing provider will review your full medication list at intake.